Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain.
Clin Exp Rheumatol
; 35 Suppl 107(5): 85-87, 2017.
Article
em En
| MEDLINE
| ID: mdl-28967370
ABSTRACT
Blockade of nerve growth factor (NGF) with antibodies is a promising strategy for treatment of chronic pain associated with osteoarthritis (OA). This narrative review describes the current status of NGF-blockade for the treatment of OA pain. We summarise briefly current evidence for the efficacy and risks of anti-NGF blockade. Two anti-NGF antibodies, tanuzemab and fasinumab, are in active development, with tanuzemabclose to completing Phase 3 trials in preparation for an application for approval for clinical use.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Osteoartrite
/
Dor
/
Fator de Crescimento Neural
/
Anticorpos Monoclonais
Limite:
Humans
Idioma:
En
Revista:
Clin Exp Rheumatol
Ano de publicação:
2017
Tipo de documento:
Article
País de afiliação:
Estados Unidos